Pediatric healthcare provider Pediatrix Medical Group (NYSE: MD) will be announcing earnings results this Thursday before the bell. Here’s what to look for.

Pediatrix Medical Group beat analysts’ revenue expectations by 3.2% last quarter, reporting revenues of $492.9 million, down 3.6% year on year. It was a stunning quarter for the company, with a beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations.

Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Pediatrix Medical Group’s revenue to decline 3% year on year to $487.3 million, a reversal from the 1.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.54 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Pediatrix Medical Group has missed Wall Street’s revenue estimates three times over the last two years.

Looking at Pediatrix Medical Group’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. The Ensign Group delivered year-on-year revenue growth of 25.9%, missing analysts’ expectations by 4.8%, and DaVita reported revenues up 9.9%, topping estimates by 3.2%. The Ensign Group traded up 13.8% following the results while DaVita was also up 21.2%.

Read our full analysis of The Ensign Group’s results here and DaVita’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. Pediatrix Medical Group’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $22.67 (compared to the current share price of $21.57).

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.